RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma

Recruiting in Palo Alto (17 mi)

+3 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Repertoire Immune Medicines

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests a new drug, RPTR-168, to see if it is safe for patients with certain types of cancer that haven't responded to other treatments. The drug is given through an IV to see if it can help fight the cancer cells.

Research Team

David Spriggs, MD

Principal Investigator

Repertoire Immune Medicines

Eligibility Criteria

Inclusion Criteria

Failure to respond to standard therapy, or for whom no appropriate therapies are available (based on the judgment of the Investigator).

Tumor refractory to or progressing following prior PD-1/PD-L1 therapy alone or in combination with an anti-CTLA-4 agent unless the patient was deemed ineligible for such treatment.

If a subject is BRAF V600E/K positive, they must have received an approved BRAF- targeted regimen prior to entering the study, unless the patient was deemed ineligible for such treatment.

See 7 more